Sino Biological Launches XPressMAX™ Cell-Free Protein Synthesis Kit to Accelerate AI-Driven Antibody Drug Discovery

Sino Biological, Inc., a global leader in recombinant technology, announced the launch of its XPressMAX Cell-Free Protein Synthesis Kit (Cat#: CFKIT02), designed to accelerate AI-powered high-throughput screening for antibody drug discovery. The kit, based on an E. coli lysate system, allows direct synthesis of target proteins and antibodies from plasmid or PCR templates in just three hours, bypassing the limitations of traditional cell-based expression methods.

The XPressMAX kit is fully supplemented with essential transcription and translation components, enabling rapid expression of VHH, scFv, Fab, and miniproteins. According to the company, the system achieves a success rate greater than 99% and supports complex disulfide bonding for native folding and bioactivity without additional enhancers. This capability is critical for validating antibody candidates identified through AI-driven screening platforms.

“Our XPressMAX is a significant advancement in research tools and reagents for next-generation therapeutic discovery,” said Dr. Rob Burgess, Chief Business Officer at Sino Biological US, Inc. “By combining rapid, reliable protein expression with intelligent screening, we are helping our partners compress antibody discovery timelines without compromising quality.”

The kit’s integration with AI-powered screening addresses a key bottleneck: the need for high-throughput expression systems that can match the speed of AI iteration. Sino Biological has already established a high-throughput cell-free expression platform that validates over 2,000 scFv/VHH molecules in three to four weeks using XPressMAX.

“AI is revolutionizing antibody screening, but it demands expression systems that can match its speed and throughput,” said Dr. Jie Zhang, Sino Biological’s General Manager. “XPressMAX achieves rapid, high-success expression of challenging proteins in as little as 3 hours.”

The announcement highlights the growing convergence of AI and biotechnology. By enabling rapid protein synthesis, the kit could significantly reduce the time and cost of early-stage drug discovery, potentially accelerating the development of new antibody-based therapies. Researchers can explore more about XPressMAX at Sino Biological’s product page or request a free sample via this form.

Sino Biological, listed on the Shenzhen Stock Exchange (301047.SZ), serves researchers in over 90 countries and maintains a stringent quality management system. The company’s US-based Center for Bioprocessing (C4B) in Houston and SignalChem Biotech in Canada provide localized support for diverse research needs.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Sino Biological Launches XPressMAX Cell-Free Protein Synthesis Kit to Accelerate AI-Driven Antibody Drug Discovery.

The post Sino Biological Launches XPressMAX™ Cell-Free Protein Synthesis Kit to Accelerate AI-Driven Antibody Drug Discovery appeared first on citybuzz.